Next Article in Journal
Ochratoxin A in Beers Marketed in Portugal: Occurrence and Human Risk Assessment
Next Article in Special Issue
Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias
Previous Article in Journal
Neurotoxin Merging: A Strategy Deployed by the Venom of the Spider Cupiennius salei to Potentiate Toxicity on Insects
Previous Article in Special Issue
A Proposal for Botulinum Toxin Type A Injection Into the Temporal Region in Chronic Migraine Headache
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials

1
Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taipei 10845, Taiwan
2
Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, Taiwan
3
Department of Physical Medicine and Rehabilitation, National Taiwan University College of Medicine, Taipei 10048, Taiwan
*
Author to whom correspondence should be addressed.
Submission received: 24 March 2020 / Revised: 9 April 2020 / Accepted: 10 April 2020 / Published: 12 April 2020
(This article belongs to the Special Issue Botulinum Neurotoxin Injection)

Abstract

:
Botulinum toxin (BoNT) injection is regarded as a promising treatment for musculoskeletal pain. However, its efficacy for treating chronic shoulder pain remains unclear. We investigated the effectiveness of BoNT injections for chronic shoulder pain by conducting a systematic search of electronic databases up to March 2020 for randomized control trials (RCTs) that used BoNT injections for chronic shoulder pain treatment. The primary outcome was the between-group comparison of pain reduction, quantified by the standardized mean difference (SMD). Nine RCTs comprising 666 patients were included and divided into two groups: one group with shoulder joint pain (n = 182) and the other group with shoulder myofascial pain (n = 484). Regarding shoulder joint pain, the efficacy of BoNT injections was similar to that of the reference treatment (SMD: −0.605, 95% confidence level [CI]: −1.242 to 0.032 versus saline; SMD: −0.180, 95% CI: −0.514 to 0.153 versus corticosteroids) at one month post-intervention, and was superior (SMD: −0.648, 95% CI: −0.1071 to −0.225 versus corticosteroids) between one and three months. Likewise, in terms of shoulder myofascial pain, the effectiveness of BoNT injections did not differ from the reference treatment (SMD: −0.212, 95% CI: −0.551 to 0.127 versus saline; SMD: 0.665, 95% CI: −0.260 to 1.590 versus dry needling and SMD: 1.093; 95% CI: 0.128 to 2.058 versus lidocaine) at one month post- intervention, and appeared superior (SMD: −0.314, 95% CI: −0.516 to −0.111 versus saline) between one and three months. Our meta-analysis revealed that BoNT injections could be a safe and effective alternative for patients with chronic shoulder pain.
Key Contribution: This work provides the most updated evidence of botulinum toxin injections in treating chronic painful shoulders.

1. Introduction

Shoulder pain, a prevalent musculoskeletal disorder, is estimated to affect 16% of the general population [1]. The lifetime prevalence of shoulder pain could be up to 67%, according to a systemic review [2]. Shoulder pain not only decreases work efficiency and life quality, but also leads to an increased economic and medical burden on the whole society [1].
The shoulder is a complicated structure. Rotator cuff tendon disorders and related bursal and joint pathology are the most common causes of shoulder pain. However, myofascial pain, characterized by the presence of myofascial trigger points (MTrPs), can develop over the shoulder region. Its diagnostic criteria consist of taut bands, hypersensitive spots, and referred pain over the affected area, and MTrPs are usually treated as the therapeutic targets [3].
Injection is an effective treatment for musculoskeletal disorders, and the commonly used injectates include corticosteroids, local anesthetics, hyaluronic acid, and high-concentration dextrose [4,5,6]. Botulinum toxin (BoNT) has been widely used in managing post-stroke spasticity, hemifacial spasm, and cervical dystonia. An increasing amount of evidence suggests that BoNT not only inhibits acetylcholine release at the neuromuscular junction, but also modulates pain by reducing nociceptive neurotransmitters and neurogenic inflammation [7]. In recent years, BoNT injections have been increasingly used to treat mild musculoskeletal disorders, like tennis elbow, knee osteoarthritis, and refractory joint pain [8,9,10]. However, its effects remain inconclusive regarding chronic shoulder pain based on available systemic reviews and meta-analyses [11,12]. Wu et al. concluded that BoNT injections were effective in treating shoulder pain compared with placebo injections [12]. However, their meta-analysis included stroke patients with hemiplegic shoulders, so the results might not be well-representative of the general population. Conversely, Ahmed et al. demonstrated that the local anesthetic injections were more effective than BoNT injections [11]. Nevertheless, their patients had heterogeneous symptoms and some of them presented with myofascial pain over all body regions. In this regard, this meta-analysis aimed to clarify whether BoNT injections were effective for the treatment of chronic shoulder pain in the general population through reviewing evidence from randomized controlled trials (RCTs).

2. Results

2.1. Study Identification and Selection

The initial search of the databases yielded 564 studies. After excluding 108 duplicated articles and 439 non-relevant articles by screening titles and abstracts, 19 studies were deemed eligible for subsequent evaluation. Ten were further excluded because four lacked a control group [10,13,14,15], five targeted myofascial pain in regions other than shoulder areas [16,17,18,19,20], and one used an enriched protocol design to assess the effect of repeated BoNT injections [14] (Figure 1).
The final meta-analysis consisted of seven 2-armed [21,22,23,24,25,26,27], one 3-armed [28], and one 4-armed [29] trials. Of the four studies investigating shoulder joint pain, one targeted patients with refractory shoulder pain [27], one targeted those with subacromial bursitis or shoulder impingement syndrome [25], one targeted those with adhesive capsulitis [24], and one was shoulder osteoarthritis [23]. The other five studies focused on patients with myofascial pain syndrome over the shoulder region [21,22,26,28,29]. This final meta-analysis included 666 participants, 62.5% of whom were women.
Regarding the reference treatments in the four studies targeting shoulder joint pain, one employed 0.9% saline injections [27] and three employed corticosteroid injections [23,24,25]. In terms of the five studies for shoulder myofascial pain, four used 0.9% saline [21,22,26,29] and one employed lidocaine and dry needling in two different arms [28]. The details of included studies are documented in Table 1, and the quality assessments are shown in Figure 2.
The type of BoNT used in the included studies was predominantly BoNT-A; only one study used BoNT-B (Myobloc®, Solstice Neurosciences, Inc., South San Francisco, CA, USA) [25]. Among the studies using BoNT-A, two used Botox® (Allergan, Irvine, CA, USA) [26,27], two used Dysport® (Ipsen Ltd., Ipsen Biopharm Ltd., Wrexham, UK) [21,22,24], and three studies did not specify the injections [23,28,29]. The dosage of BoNT varied across different brands. Regarding shoulder joint pain, the common dosage for injection was 100 U of Botox® (BoNT-A), 200 U of Dysport® (BoNT-A) or 2500 U of Myobloc® (BoNT-B). In terms of shoulder myofascial pain, the dosage for injection per trigger point ranged from 5 to 40 U of BoNT-A. The details of regimens, injection techniques, outcome measurements, and follow-up durations are listed in Table 2.

2.2. Outcomes

2.2.1. Shoulder Joint Pain

Regarding the visual analogue scale (VAS) at one month after intervention, only one trial compared BoNT injections with saline [27]; the standardized mean difference (SMD) was −0.605 (95% CI, −1.242 to 0.032) (Figure 3). The other three trials used corticosteroid injections as comparisons and their summarized SMD was −0.180 (95% CI, −0.514 to 0.153; I square < 0.001) [23,24,25]. None of the aforementioned effect sizes reached statistical significance. In terms of VAS between one and three months after intervention, only the studies comparing corticosteroid injections had available data. The pooled SMD was −0.648 (95% CI, −0.1071 to −0.225), indicating a significantly superior outcome of BoNT than corticosteroids.

2.2.2. Shoulder Myofascial Pain

In a triple-arm trial, the SMDs of the VAS at one month post- intervention were 0.665 (95% CI, −0.260 to 1.590) comparing dry needling, and 1.093 (95% CI, 0.128 to 2.058) comparing lidocaine injections [28] (Figure 4). A 4-armed RCT with 3 different doses of BoNT compared with saline was merged into one group to compare the effects after saline injections [29]. Four studies compared saline injections, and the pooled effect size at one month post- intervention was −0.212 (95% CI, −0.551 to 0.127; I square: 68.8%) [21,22,26,29]. Regarding the VAS between one and three months, the summarized SMD comparing saline from 3 studies was −0.314 (95% CI, −0.516 to −0.111; I square: 3.3%), showing a significant effect favoring BoNT injections.

2.3. Adverse Events

Among the 9 enrolled studies, 8 trials clearly reported the adverse events [21,22,24,25,26,27,28,29]. Most documented adverse events related to BoNT injections were of mild to moderate severity, such as temporary muscle pain or soreness after treatments. In one study [27], three cases in the BoNT-A group and nine cases in the reference group reported serious adverse events after injections (Table 2). However, most of the events (e.g., chest pain, atrial fibrillation, abdominal pain) were related to their underlying diseases and not to the BoNT injections.

2.4. Publication Bias

2.4.1. Shoulder Joint Pain

Significant publication bias was detected using the Egger test (p = 0.03) regarding the VAS at one month post-injection for myofascial pain. However, there was no significant publication bias between one to three months post-injection. The corresponding funnel plot is shown in Figure S1.

2.4.2. Shoulder Myofascial Pain

The p-value of the Egger test for the VAS at one month was 0.047, indicating significant publication bias. No significant publication bias was detected regarding the VAS between one to three months post-injection. The corresponding funnel plot is shown in Figure S2.

3. Discussion

3.1. Summary of the Meta-Analysis

The present meta-analysis included available RCTs to investigate the efficacy of BoNT injections in chronic shoulder pain, revealing that the BoNT injection was similar to the reference treatments regarding short-term effectiveness. Compared with corticosteroid and saline injections, BoNT injections yielded more symptom relief between one to three months following treatment in terms of joint and myofascial pain over the shoulder region.

3.2. Botulinum Toxin (BoNT) Injection in Shoulder Joint Pain

Pain over the shoulder joint is predominantly derived from degeneration and chronic inflammation of the rotator cuff tendons and glenohumeral joint. Corticosteroid injections are widely used in the management of shoulder pain based on its anti-inflammatory potential, and its effectiveness has been proven by several clinical studies [30,31,32,33]. On the other hand, animal studies demonstrated that BoNT injections could inhibit release of pain mediators, including glutamate, substance P, and calcitonin gene-related peptides [34,35,36]. Hence, based on our analysis, inflammatory shoulder pain might be modulated by blocking nociception by injecting BoNT, whose short-term efficacy has been shown to be similar to corticosteroid injections.
However, a significantly better outcome of BoNT injections was observed at the mid-term follow-up, implying a more durable effect of BoNT than corticosteroids. Recurrent pain after corticosteroid injections was common [37,38], although the timing of the recurrence varies with initial clinical manifestation and disease severity [32]. Possible explanations for the lasting effect of pain reduction after BoNT injections include: (1) the duration of action of BoNT was longer than corticosteroids (approximately 3 months vs. 8 weeks) [37,39] and (2) BoNT inhibits not only pain mediators, but also impedes downstream neurogenic inflammation [40,41]. Neurogenic inflammation is a phenomenon of reduced sensory nerve thresholds and increased activation of sensory neurons, induced by excitation of nociceptors following the stimulation of pain mediators [42]. Therefore, pain relief after BoNT injections in chronic shoulder joint pain might be attributed to the interference of afferent pain signals and modulation of neurogenic inflammation, which could not be achieved by the administration of corticosteroids [43].

3.3. BoNT Injection in Shoulder Myofascial Pain

For shoulder myofascial pain, our meta-analysis revealed no significant difference in short-term efficacy between BoNT injections and other comparative treatments, like dry needling and injection of saline and lidocaine. Immediate analgesia after injections on MTrPs can be attributed to the needling effect or temporary analgesia after local anesthetics [44]. Moreover, an injection itself may increase muscle circulation [45], which could be achieved both in the BoNT injections and reference groups. Nevertheless, our results revealed that BoNT injections had better mid-term pain relief than saline injections, possibly resulting from the pharmacological effect of BoNT. Some studies showed that pain from MTrPs was the consequence of dysfunction at the motor endplates with subsequent chronic muscle contraction [46]. Administration of BoNT on MTrPs has been shown to reduce acetylcholine release at the neuromuscular junction possible relief of myofascial pain after muscle relaxation. Moreover, the accumulation of oxidative stress and the depletion of the energy supply in MTrPs can reinforce peripheral sensitization of nociception, leading to centralization of pain perception [47]. BoNT injections may inhibit pain mediators released peripherally to decrease central sensitization. Importantly, the average duration of action of BoNT is 12 weeks [48], which also explained why BoNT injections had a longer effect on shoulder myofascial pain than saline injections.

3.4. Type and Dosage of BoNT for Injection

Among all the enrolled studies, only one trial used BoNT-B (Myobloc®) [25]. This was probably due to higher post-injection pain, more symptoms of dysautonomia, shorter duration of action, and an increased incidence of immunogenicity after the administration of BoNT-B. [49,50]. According to previous literature [51,52], the effective dosage of 100 units (U) of Botox® is equivalent to 200–300 U of Dysport® or 5000 U of Myobloc®. After conversion, we found the dosage of BoNT for intra-bursal injections was roughly half of the dosage for intra-articular injections of our included trials.
Regarding shoulder myofascial pain, the total dosage depends on the dose at each injection site and the number of trigger points. The maximum dose allowed for injections on a patient were predesignated in 3 studies [21,22,26], which was up to 35 U of Botox® [26] and 400 U of Dysport® [21,22]. Caution should be taken regarding the upper limit of BoNT administered per patient, especially for those with preexisting neuromuscular diseases.

3.5. Clinical Implications

This meta-analysis is in favor of BoNT injections for the treatment of chronic shoulder pain. Regarding shoulder joint pain, intra-articular or intra-bursal administration of BoNT has a similar short-term, but better mid-term analgesic effect, compared with corticosteroid injections. In terms of shoulder myofascial pain, BoNT injections could achieve longer lasting pain relief than saline injections.

3.6. Limitations

This meta-analysis has limitations. First, the patients in the enrolled studies had different etiologies. Therefore, we separated them into two groups for analysis based on their causes of pain. Second, the available follow-up durations of all included trials were only up to three months, so the long-term effects of BoNT injections for chronic shoulder pain is unknown. Third, whether BoNT injections could improve shoulder function was not within the scope of this meta-analysis; future studies are needed to explore these questions. Lastly, the number of the studies eligible for inclusion was relatively small when limiting the research type only in RCTs. This might mitigate the power of the conclusion derived from the present meta-analysis. Nevertheless, some case series investigating BoNT injections also demonstrated pain reduction and functional improvement in shoulder joint and myofascial pain [13,53], which were compatible with our findings.

4. Conclusions

BoNT injections had similar short-term efficacy as the reference treatments like corticosteroid and saline injections for relieving chronic shoulder pain. Its effect was superior to the reference treatments between one to three months following injections. The majority of adverse effects pertinent to BoNT injections were temporary and reversible and their severity was mild to moderate. Intra-articular, -bursal, and -muscular administration of BoNT is considered to be a safe and effective alternative for patients with chronic painful shoulders.

5. Methods

5.1. Search Strategy and Criteria

Two electronic databases, PubMed and Embase, were scrutinized for relevant articles published from the earliest record to Jan 2020. We also searched the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov database for suitable references. Moreover, we manually examined the reference lists of the included articles for pertinent trials. The key terms, “botulinum toxin”, “shoulder”, and “myofascial pain” were entered as the medical subject heading and text words for literature searches. The search strategy is presented in Appendix A. The current meta-analysis was not conducted based on any registered or published protocols.

5.2. Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1) RCTs, (2) enrollment of patients with shoulder pain, including tendon and joint related disorders (including adhesive capsulitis, subacromial impingement and osteoarthritis) and myofascial pain syndrome [54], and (3) quantitative measurements of pain before and after treatments. Furthermore, studies investigating myofascial pain, but not covering the shoulder region, and those recruiting stroke patients with hemiplegic shoulders were not included. Animal studies, case reports, case series, single-arm longitudinal follow-up studies, and quasi-experimental comparative studies were excluded from the present meta-analysis.

5.3. Data Collection and Abstraction

Two authors (P.-C.H. and W.-T.W.) independently screened and evaluated whether the retrieved articles were eligible and met the criteria of inclusion. The information of patient demographics (age, gender ratio, disease duration and type, regimen and site for injection, and the parameters of outcome measurements) were recorded by both authors concurrently using the predesignated evaluation form. The corresponding authors would confirm the correctness of the retrieved data.

5.4. Assessment of Study Quality

The methodological quality of the enrolled studies was assessed using the Cochrane Risk of Bias Tool for RCTs [55]. The risk of bias was classified as either high, low, or unclear. The quality assessment was based on the following aspects: sequence generation (selection bias), allocation concealment (selection bias), blinding of patients and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective outcome reporting (reporting bias). Any discrepancy in opinions of assessments between the two evaluators were solved either through discussion or by the judgment of the corresponding author.

5.5. Meta-Analysis Methodology

The change in the VAS of pain before and after treatment was treated as the primary outcome. The VAS was extracted at or closest to the following points: baseline, within one month and between one to three months after the intervention. The summarized SMD of the VAS changes between two treatment arms was used to compare the effectiveness of BoNT injections with other injectates or approaches [56].
The random effects model was applied for pooling of the effect sizes due to the variations in study designs (such as drug dosage, injection technique, and injection numbers) across the included trials. An SMD of 0.2, 0.5, and 0.8 is considered a small, moderate, and large effect size, respectively [57]. The I-square and Cochran’s Q statistics were used to evaluate the degree of heterogeneity among studies. An I-square value of 25%, 50%, and 75% was considered low, moderate, and high heterogeneity, respectively [58]. The symmetry of the effect size distribution on the funnel plot and the result from the Egger’s test were used to assess the potential publication bias. All the analyses were conducted using Comprehensive Meta-analysis Software version 3 (Biostat, Englewood, NJ, USA), and p < 0.05 was considered statistically significant.

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/2072-6651/12/4/251/s1, Figure S1: Funnel plot for the comparisons of the standardized mean difference at (A) one month and (B) between one and three months after injection for shoulder joint pain, Figure S2: Funnel plot for the comparisons of the standardized mean difference at (A) one month and (B) between one and three months after injection for shoulder myofascial pain.

Author Contributions

Conceptualization, K.-V.C.; methodology, K.-V.C. and P.-C.H.; software, K.-V.C.; validation, K.-V.C. and P.-C.H.; investigation, P.-C.H. and W.-T.W.; writing—original draft preparation, P.-C.H.; writing—review and editing, K.-V.C.; supervision, W.-T.W.; and D.-S.H. All authors have read and agreed to the published version of the manuscript.

Funding

The current research project was supported by (1) National Taiwan University Hospital, Bei-Hu Branch; (2) Ministry of Science and Technology (MOST 106-2314-B-002-180-MY3); and [54] Taiwan Society of Ultrasound in Medicine.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A. Strategy of Literature Search

PubMed
  • (((((((botulinum toxin) OR botox) OR onabotulinumtoxina) OR rimabotulinumtoxinb) OR abobotulinumtoxina) OR incobotulinumtoxin) OR dysport) OR xeomin
  • ((((((shoulder pain) OR rotator cuff) OR bursitis) OR impingement syndrome) OR myofascial pain) OR adhesive capsulitis) OR trigger point
  • (((((randomized controlled trial) OR controlled clinical trial) OR randomized) OR placebo) OR randomly) OR controlled
  • 1 and 2 and 3
Embase
  • ‘botulinum toxin’ OR ‘botox’ OR ‘onabotulinumtoxina’ OR rimabotulinumtoxinb OR abobotulinumtoxina OR incobotulinumtoxin OR dysport OR xeomin
  • ‘shoulder pain’ OR ‘rotator cuff’ OR bursitis OR ‘impingement syndrome’ OR ‘myofascial pain’ OR ‘adhesive capsulitis’ OR ‘trigger point’
  • ‘randomized controlled trial’ OR ‘controlled clinical trial’ OR randomized OR ‘placebo’ OR ‘randomly’ OR ‘controlled’
  • 1 and 2 and 3

References

  1. Urwin, M.; Symmons, D.; Allison, T.; Brammah, T.; Busby, H.; Roxby, M.; Simmons, A.; Williams, G. Estimating the burden of musculoskeletal disorders in the community: The comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann. Rheum. Dis. 1998, 57, 649–655. [Google Scholar] [CrossRef] [PubMed]
  2. Luime, J.J.; Koes, B.W.; Hendriksen, I.J.; Burdorf, A.; Verhagen, A.P.; Miedema, H.S.; Verhaar, J.A. Prevalence and incidence of shoulder pain in the general population; a systematic review. Scand. J. Rheumatol. 2004, 33, 73–81. [Google Scholar] [CrossRef] [PubMed]
  3. Fernandez-de-Las-Penas, C.; Dommerholt, J. International Consensus on Diagnostic Criteria and Clinical Considerations of Myofascial Trigger Points: A Delphi Study. Pain Med. 2018, 19, 142–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Monseau, A.J.; Nizran, P.S. Common injections in musculoskeletal medicine. Prim. Care 2013, 40, 987–1000. [Google Scholar] [CrossRef]
  5. Reeves, K.D.; Sit, R.W.S.; Rabago, D.P. Dextrose Prolotherapy: A Narrative Review of Basic Science, Clinical Research, and Best Treatment Recommendations. Phys. Med. Rehabil. Clin. 2016, 27, 783–823. [Google Scholar] [CrossRef]
  6. Frizziero, A.; Vittadini, F.; Oliva, F.; Abatangelo, G.; Bacciu, S.; Bernardi, A.; Bossa, M.; Buda, R.; Buonocore, D.; Calderazzi, F.; et al. I.S.Mu.L.T. Hyaluronic acid injections in musculoskeletal disorders guidelines. Muscle Ligaments Tendons J. 2018, 8, 364–398. [Google Scholar] [CrossRef] [Green Version]
  7. Bach-Rojecky, L.; Salkovic-Petrisic, M.; Lackovic, Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur. J. Pharm. 2010, 633, 10–14. [Google Scholar] [CrossRef] [Green Version]
  8. Hayton, M.J.; Santini, A.J.; Hughes, P.J.; Frostick, S.P.; Trail, I.A.; Stanley, J.K. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J. Bone Jt. Surg 2005, 87, 503–507. [Google Scholar] [CrossRef]
  9. Boon, A.J.; Smith, J.; Dahm, D.L.; Sorenson, E.J.; Larson, D.R.; Fitz-Gibbon, P.D.; Dykstra, D.D.; Singh, J.A. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: A pilot study. PM R 2010, 2, 268–276. [Google Scholar] [CrossRef]
  10. Mahowald, M.L.; Singh, J.A.; Dykstra, D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox. Res. 2006, 9, 179–188. [Google Scholar] [CrossRef]
  11. Ahmed, S.; Subramaniam, S.; Sidhu, K.; Khattab, S.; Singh, D.; Babineau, J.; Kumbhare, D.A. Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis. Clin. J. Pain 2019, 35, 353–367. [Google Scholar] [CrossRef] [PubMed]
  12. Wu, T.; Fu, Y.; Song, H.X.; Ye, Y.; Dong, Y.; Li, J.H. Effectiveness of Botulinum Toxin for Shoulder Pain Treatment: A Systematic Review and Meta-Analysis. Arch. Phys. Med. Rehabil. 2015, 96, 2214–2220. [Google Scholar] [CrossRef] [PubMed]
  13. Kim, D.Y.; Kim, J.M. Safety and Efficacy of PrabotulinumtoxinA (Nabota((R))) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study. Toxins 2018, 10, 355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Nicol, A.L.; Wu, I.I.; Ferrante, F.M. Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design. Anesth Analg 2014, 118, 1326–1335. [Google Scholar] [CrossRef] [Green Version]
  15. Singh, J.A.; Mahowald, M.L.; Kushnaryov, A.; Goelz, E.; Dykstra, D. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J. Clin. Rheumatol. 2009, 15, 35–38. [Google Scholar] [CrossRef]
  16. Kwanchuay, P.; Petchnumsin, T.; Yiemsiri, P.; Pasuk, N.; Srikanok, W.; Hathaiareerug, C. Efficacy and Safety of Single Botulinum Toxin Type A (Botox(R)) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study. J. Med. Assoc. Thai. 2015, 98, 1231–1236. [Google Scholar]
  17. Lew, H.L.; Lee, E.H.; Castaneda, A.; Klima, R.; Date, E. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: A pilot study. Arch. Phys. Med. Rehabil. 2008, 89, 75–80. [Google Scholar] [CrossRef]
  18. Miller, D.; Richardson, D.; Eisa, M.; Bajwa, R.J.; Jabbari, B. Botulinum neurotoxin-A for treatment of refractory neck pain: A randomized, double-blind study. Pain Med. 2009, 10, 1012–1017. [Google Scholar] [CrossRef] [Green Version]
  19. Wheeler, A.H.; Goolkasian, P.; Gretz, S.S. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23, 1662–1666. [Google Scholar] [CrossRef]
  20. Wheeler, A.H.; Goolkasian, P.; Gretz, S.S. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001, 94, 255–260. [Google Scholar] [CrossRef]
  21. Benecke, R.; Heinze, A.; Reichel, G.; Hefter, H.; Gobel, H.; on behalf of the Dysport myofascial pain study group. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: How do fixed-location injections compare with trigger point-focused injections? Pain Med. 2011, 12, 1607–1614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Gobel, H.; Heinze, A.; Reichel, G.; Hefter, H.; Benecke, R.; on behalf of the Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006, 125, 82–88. [Google Scholar] [CrossRef] [PubMed]
  23. Hashemi, S.M.; Khamene, S.M.H.; Naderi-Nabi, B.; Ghasemi, M. Effects of ultrasound-guided intraarticular botox vs. corticosteroids for shoulder osteoarthritis. Anaesth. Pain Intensive Care 2019, 22, 355–360. [Google Scholar]
  24. Joo, Y.J.; Yoon, S.J.; Kim, C.W.; Lee, J.H.; Kim, Y.J.; Koo, J.H.; Song, S.H. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann. Rehabil. Med. 2013, 37, 208–214. [Google Scholar] [CrossRef] [PubMed]
  25. Lee, J.H.; Lee, S.H.; Song, S.H. Clinical effectiveness of botulinum toxin type B in the treatment of subacromial bursitis or shoulder impingement syndrome. Clin. J. Pain 2011, 27, 523–528. [Google Scholar] [CrossRef] [PubMed]
  26. Ojala, T.; Arokoski, J.P.; Partanen, J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: A double-blind, randomized, and controlled crossover trial. Clin. J. Pain 2006, 22, 90–96. [Google Scholar] [CrossRef]
  27. Singh, J.A.; Mahowald, M.L.; Noorbaloochi, S. Intra-articular botulinum toxin A for refractory shoulder pain: A randomized, double-blinded, placebo-controlled trial. Transl. Res. 2009, 153, 205–216. [Google Scholar] [CrossRef]
  28. Kamanli, A.; Kaya, A.; Ardicoglu, O.; Ozgocmen, S.; Zengin, F.O.; Bayik, Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol. Int. 2005, 25, 604–611. [Google Scholar] [CrossRef]
  29. Ferrante, F.M.; Bearn, L.; Rothrock, R.; King, L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005, 103, 377–383. [Google Scholar] [CrossRef]
  30. Buchbinder, R.; Green, S.; Youd, J.M. Corticosteroid injections for shoulder pain. Cochrane Database Syst. Rev. 2003. [Google Scholar] [CrossRef]
  31. Wu, W.T.; Chang, K.V.; Han, D.S.; Chang, C.H.; Yang, F.S.; Lin, C.P. Effectiveness of Glenohumeral Joint Dilatation for Treatment of Frozen Shoulder: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Sci. Rep. 2017, 7, 10507. [Google Scholar] [CrossRef] [PubMed]
  32. Chang, K.V.; Wu, W.T.; Han, D.S.; Ozcakar, L. Static and Dynamic Shoulder Imaging to Predict Initial Effectiveness and Recurrence After Ultrasound-Guided Subacromial Corticosteroid Injections. Arch. Phys. Med. Rehabil. 2017, 98, 1984–1994. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, J.C.; Chang, K.V.; Wu, W.T.; Han, D.S.; Ozcakar, L. Ultrasound-Guided Standard vs Dual-Target Subacromial Corticosteroid Injections for Shoulder Impingement Syndrome: A Randomized Controlled Trial. Arch. Phys. Med. Rehabil. 2019, 100, 2119–2128. [Google Scholar] [CrossRef] [PubMed]
  34. Lucioni, A.; Bales, G.T.; Lotan, T.L.; McGehee, D.S.; Cook, S.P.; Rapp, D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. Bju Int. 2008, 101, 366–370. [Google Scholar] [CrossRef] [PubMed]
  35. Durham, P.L.; Cady, R.; Cady, R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004, 44, 35–42; discussion 42–43. [Google Scholar] [CrossRef] [PubMed]
  36. Meng, J.; Ovsepian, S.V.; Wang, J.; Pickering, M.; Sasse, A.; Aoki, K.R.; Lawrence, G.W.; Dolly, J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 2009, 29, 4981–4992. [Google Scholar] [CrossRef]
  37. Gaujoux-Viala, C.; Dougados, M.; Gossec, L. Efficacy and safety of steroid injections for shoulder and elbow tendonitis: A meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 2009, 68, 1843–1849. [Google Scholar] [CrossRef]
  38. Mohamadi, A.; Chan, J.J.; Claessen, F.M.; Ring, D.; Chen, N.C. Corticosteroid Injections Give Small and Transient Pain Relief in Rotator Cuff Tendinosis: A Meta-analysis. Clin. Orthop. Relat. Res. 2017, 475, 232–243. [Google Scholar] [CrossRef] [Green Version]
  39. Hallett, M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. Toxicon 2015, 107, 64–67. [Google Scholar] [CrossRef] [Green Version]
  40. Jankovic, J.; Schwartz, K. Botulinum toxin injections for cervical dystonia. Neurology 1990, 40, 277–280. [Google Scholar] [CrossRef]
  41. Gobel, H.; Heinze, A.; Heinze-Kuhn, K.; Jost, W.H. Evidence-based medicine: Botulinum toxin A in migraine and tension-type headache. J. Neurol. 2001, 248, 34–38. [Google Scholar] [CrossRef] [PubMed]
  42. Gangadharan, V.; Kuner, R. Pain hypersensitivity mechanisms at a glance. Dis. Models Mech. 2013, 6, 889–895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Freitas, J.O.; Quieregatto, P.R.; Hochman, B.; Lapin, G.A.; Mella, S.M.; Maximino, J.R.; Chadi, G.; Ferreira, L.M. Does dexamethasone act in neuropeptides SP and CGRP in neurogenic inflammation of the skin? An experimental study. Acta Cir. Bras. 2015, 30, 523–528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Lewit, K. The needle effect in the relief of myofascial pain. Pain 1979, 6, 83–90. [Google Scholar] [CrossRef]
  45. Cagnie, B.; Barbe, T.; De Ridder, E.; Van Oosterwijck, J.; Cools, A.; Danneels, L. The influence of dry needling of the trapezius muscle on muscle blood flow and oxygenation. J. Manip. Physiol. 2012, 35, 685–691. [Google Scholar] [CrossRef] [PubMed]
  46. Simons, D.G.; Hong, C.Z.; Simons, L.S. Endplate potentials are common to midfiber myofacial trigger points. Am. J. Phys. Med. Rehabil. 2002, 81, 212–222. [Google Scholar] [CrossRef]
  47. Fricton, J. Myofascial Pain: Mechanisms to Management. Oral Maxillofac. Surg. Clin. 2016, 28, 289–311. [Google Scholar] [CrossRef]
  48. Fonfria, E.; Maignel, J.; Lezmi, S.; Martin, V.; Splevins, A.; Shubber, S.; Kalinichev, M.; Foster, K.; Picaut, P.; Krupp, J.; et al. The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins 2018, 10, 208. [Google Scholar] [CrossRef] [Green Version]
  49. Bentivoglio, A.R.; Del Grande, A.; Petracca, M.; Ialongo, T.; Ricciardi, L. Clinical differences between botulinum neurotoxin type A and B. Toxicon 2015, 107, 77–84. [Google Scholar] [CrossRef]
  50. Woodruff, B.A.; Griffin, P.M.; McCroskey, L.M.; Smart, J.F.; Wainwright, R.B.; Bryant, R.G.; Hutwagner, L.C.; Hatheway, C.L. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. J. Infect. Dis. 1992, 166, 1281–1286. [Google Scholar] [CrossRef]
  51. Blitzer, A. Botulinum toxin A and B: A comparative dosing study for spasmodic dysphonia. Otolaryngol. Head Neck Surg. 2005, 133, 836–838. [Google Scholar] [CrossRef] [PubMed]
  52. Scaglione, F. Conversion Ratio between Botox(R), Dysport(R), and Xeomin(R) in Clinical Practice. Toxins 2016, 8, 65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Cinone, N.; Letizia, S.; Santoro, L.; Gravina, M.; Amoruso, L.; Molteni, F.; Ranieri, M.; Santamato, A. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: A case series summary and review of the literature. J. Pain Res. 2018, 11, 1239–1245. [Google Scholar] [CrossRef] [Green Version]
  54. Mysiew, W.J.; Colachis, S.C., 3rd. The pronator syndrome. An evaluation of dynamic maneuvers for improving electrodiagnostic sensitivity. Am. J. Phys. Med. Rehabil. 1991, 70, 274–277. [Google Scholar] [CrossRef] [PubMed]
  55. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Higgins, J.P.; Altman, D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.; et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj 2011, 343, d5928. [Google Scholar] [CrossRef] [Green Version]
  57. Chang, K.V.; Wu, W.T.; Hung, C.Y.; Han, D.S.; Yang, R.S.; Chang, C.H.; Lin, C.P. Comparative Effectiveness of Suprascapular Nerve Block in the Relief of Acute Post-Operative Shoulder Pain: A Systematic Review and Meta-analysis. Pain Physician 2016, 19, 445–456. [Google Scholar]
  58. Lipsey, M.W.; Wilson, D.B. Practical Meta-analysis; Sage Publications, Inc.: Thousand Oaks, CA, USA, 2001; p. ix, 247. [Google Scholar]
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the study selection process.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the study selection process.
Toxins 12 00251 g001
Figure 2. Summary graph (A) and table (B) of risk for bias of enrolled studies. Green (+): low risk of bias; red (-): high risk of bias; blank: unclear risk of bias.
Figure 2. Summary graph (A) and table (B) of risk for bias of enrolled studies. Green (+): low risk of bias; red (-): high risk of bias; blank: unclear risk of bias.
Toxins 12 00251 g002
Figure 3. Forest plot of pain reduction from botulinum toxin injection for shoulder joint pain at 1 month and between 1–3 months after injection. VAS, visual analogue scale of pain. The square indicates the point estimate and the rhombus represents the pooled effect size.
Figure 3. Forest plot of pain reduction from botulinum toxin injection for shoulder joint pain at 1 month and between 1–3 months after injection. VAS, visual analogue scale of pain. The square indicates the point estimate and the rhombus represents the pooled effect size.
Toxins 12 00251 g003
Figure 4. Forest plot of standardized mean differences in pain reduction of botulinum toxin versus reference treatment for myofascial pain over the shoulder region within 1 month, and 1–3 months after injection. The square indicates the point estimate and the rhombus represents the pooled effect size.
Figure 4. Forest plot of standardized mean differences in pain reduction of botulinum toxin versus reference treatment for myofascial pain over the shoulder region within 1 month, and 1–3 months after injection. The square indicates the point estimate and the rhombus represents the pooled effect size.
Toxins 12 00251 g004
Table 1. Summary of the retrieved trials investigating botulinum toxin on patients with chronic shoulder pain.
Table 1. Summary of the retrieved trials investigating botulinum toxin on patients with chronic shoulder pain.
StudyDiagnosis Enrolled Sample Number (Male/Female)Average Age, YearsPain Duration, MonthsDouble BlindRandomizationAllocation ConcealmentFunding Source
Shoulder Joint Pain
Singh et al. 2009 [27]Refractory shoulder painBoNT-A: 21(20/1)
Saline: 22 (22/0)
BoNT-A: 72.1 ± 1.9
Saline: 70.2 ± 2.6
BoNT-A:96 ± 24
Saline: 132 ± 36
YesRandom tableYesArthritis Foundation North Central Chapter grant;
VA Scholar grant from the Center for Epidemiological and Clinical Research; Minneapolis VA Medical Center.
NIH CTSA Award;
Allergan Pharmaceuticals, Inc.
Lee et al. 2011 [25]Subacromial bursitis or shoulder impingement syndromeBoNT-B: 31 (14/17)
Steroid: 30 (11/19)
BoNT-B: 57.9 ± 10.1
Steroid: 55.8 ± 9.1
BoNT-B:8.2 ± 5.5
Steroid: 8.2 ± 7
YesUnclearYesWooridul Spine Foundation, Korea
Joo et al. 2013 [24] Adhesive capsulitisBoNT-A: 15(9/6)
Steroid: 13 (8/5)
BoNT-A: 55.0 ± 9.7
Steroid: 53.3 ± 13.7
BoNT-A: 8.7 ± 7.2
Steroid: 5.7 ± 1.5
NoRandom tableUnclearNot mentioned
Hashemi et al. 2018 [23]Shoulder osteoarthritis50 (24/26) in total:
BoNT-A: 25 Steroid: 25
Mean age: 56 ± 7.6 in total>3 in totalYesUnclearUnclearNot mentioned
Shoulder Myofascial Pain Syndrome
Kamanli et al. 2005 [28]Trigger point located at cervical,
back, or shoulder muscles
29 participants (6/23) in total:
BoNT-A:9
Lidocaine:10
Dry needling:10
BoNT-A: 38.3 ± 5.26
Lidocaine: 37.30 ± 9.76
Dry needling: 37.20 ± 8.08
BoNT-A: 49.20 ± 34.96
Lidocaine: 32.50 ± 21.99
Dry needling: 50.66 ± 19.92
NoUnclearUnclearNot mentioned
Ferrante et al. 2005 [29]Cervicothoracic and shoulder myofascial PainBoNT-A 10U/TP:32 (13/19)
BoNT-A 25U/TP:34 (13/21)
BoNT-A 50U/TP:31 (11/20)
saline: 35 (15/20)
BoNT-A 10U/TP: 43.3 ± 10.9
BoNT-A 25U/TP: 46.6 ± 15
BoNT-A 50U/TP: 46.5 ± 12.21
Saline: 45.3 ± 10.1
>3 YesRandom tableUnclearNot mentioned
Ojala et al. 2006 [26]Neck-shoulder myofascial
pain
31 (3/28) in total: BoNT-A: 15
Saline: 16
BoNT-A: 44.9 ± 7.6
Saline: 43.8 ± 8.1
BoNT-A: 10.5 ± 9.9
Saline: 9.5 ± 7.6
YesBlock randomizationUnclear Kuopio University Hospital, Finland
Göbel et al. 2006 [22]Upper back and/or shoulder
myofascial pain syndrome
BoNT-A: 74 (16/61)
Saline: 70 (16/54)
BoNT-A: 44 ± 12
Saline: 45 ± 11
BoNT-A: 18 ± 6
Saline: 19 ± 9
YesBlock randomizationYesNot mentioned
Benecke et al. 2011 [21]Myofascial pain syndrome
affecting cervical muscles of the back and shoulder
BoNT-A: 76(32/44)
Saline: 72 (20/52)
BoNT-A: 48 ± 13
Saline: 45 ± 10
BoNT-A: 19 ± 70
Saline: 19 ± 68
YesBlock randomizationYesIpsen, UK
BoNT: botulinum toxin.
Table 2. Summary of intervention details of botulinum toxin injection in the retrieved trials.
Table 2. Summary of intervention details of botulinum toxin injection in the retrieved trials.
Author, YearBotulinum Toxin Type (Brand)Dose/Volume *Reference TreatmentInjection TechniqueOutcome MeasurementFollow UpAdverse Effects
Shoulder Joint Pain
Singh et al. 2009 [27]BoNT-A (Botox®),100 U/1 mL pretreated with 2 mL of 1% lidocaine1 mL of 0.9% saline solution + 2 mL of 1% lidocaineLandmark guided, posterior approach to glenohumeral jointVAS; SPADI; ROM (flexion + abduction), short-form McGill Pain Questionnaire; SF-36; proportion of responders1 monthBoTN-A: 50 AEs (3 serious AEs:2 chest pain,1 scheduled cataract surgery)
Placebo: 46 AEs (9 serious AEs:1 chest pain, 2 atrial fibrillation, 1 small-bowel obstruction, 1 abdominal pain, 1 hematuria, 1 acute renal failure, 1 ear pain and 1 anxiety attack)
Lee et al. 2011 [25]BoNT-B (Myobloc®)2500 U/0.5 mL + 0.5% lidocaine 2 mLTriamcinolone 40 mg + 2 mL of 0.5% lidocaine Ultrasound-guided subacromial bursa injectionNRS, DASH, Shoulder ROM (abduction)1 and 3 monthsBoTN-B: 2 AEs (injection site discomfort)
Triamcinolone: 3 AEs (injection site discomfort)
No serious AEs
Joo et al. 2013 [24] BoNT-A (Dysport®)200 U/2 mLTriamcinolone 20 mg (1 mL) + 1 mL of 0.9% saline solution.Fluoroscopic guidance, anterior approach to glenohumeral jointNRS; ROM (active flexion, abduction and passive flexion, abduction, external rotation and internal rotation)2,4 and 8 weeksBoTN-B: 1 AEs (flu-like symptoms)
Triamcinolone: 2 AEs (flu-like symptoms)
No serious AEs
Hashemi et al. 2018 [23]BoNT-A
(not mentioned)
100 U/5 mLTriamcinolone 10 mg (4 mL) + 4 mL of 0.9% saline solution.Ultrasound-guided glenohumeral joint injection VAS; ROM (External rotation, internal rotation and abduction)2 and 12 weeksUnclear
Shoulder Myofascial Pain Syndrome
Kamanli et al. 2005 [28]BoNT-A
(not mentioned)
10–20 U/1–2 mL (22 injections in 9 patients)(1) Lidocaine group: 1 mL of 0.5% lidocaine solution (32 injections in 10 patients)
(2) Dry needling: empty syringe (33 injections in 10 patients)
Palpation guided trigger point injectionVAS; cervical ROM; Pressure pain threshold; Pain score§; Hamilton Anxiety and Depression Inventory; Nottingham Health Profile1 monthBoNT-A: 9AEs (5 fatigue, 3 muscle pain, 1 headache)
Lidocaine: 6 AEs (3 coldness and burning sensation, 3 paresthesia)
No serious AEs
Ferrante et al. 2005 [29]BoNT-A
(not mentioned)
10 U/0.5 mL, 25 U/0.5 mL and 50 U/0.5 mL depending on different arms; maximum 250 U on one patient 0.5 mL 0.9% saline Palpation guided trigger point injectionVAS and sum of pain intensity differences; Rescue medication;
Pain pressure threshold; SF-36
0,1,2,3,4,5,6,7,8,12 weeksBoNT-A: 3 AEs (flu-like symptoms)
No serious AEs
Ojala et al. 2006 [26]BoNT-A (Botox®)5U/0.05 mL
(range 15–35 U, mean 28 ± 6 U)
0.05 mL 0.9% saline Palpation guided trigger point injectionVAS; Self-assessment
of the efficacy; Pressure pain threshold
4 weeksBoNT-A: 7 AEs (1 injection site pain, 2 vertigo, 1 sweating, 1 hands fatigue, 2 headache)
Saline: 4 AEs (1 injection site pain, 1 vertigo, 1 hands fatigue, 1 eyelids swelling)
No serious AEs
Göbel et al. 2006 [22]BoNT-A (Dysport®)40 U/0.4 mL
(10 trigger points)
0.4 mL of 0.9% saline solutionPalpation guided Pain intensity§4,8 and 12 weeksBoNT-A: 31 AEs
Saline: 11 AEs
No serious AEs
Benecke et al. 2011 [21]BoNT-A (Dysport®)40 U/0.4 mL (10 fixed injection sites)0.4 mL of 0.9% saline solution10 standardized predetermined injection sites in the head, neck, and shoulder.Pain intensity§
Global evaluation of treatment
4,8 and 12 weeksBoNT-A: 33 AEs
Saline: 29 AEs
No serious AEs
* The information is shown as the dose and volume per site regarding for the treatment of myofascial pain. § Pain intensity and Pain score were four-point scale, while 1 (no pain) to 4 (severe pain) for Pain intensity and 0 (no pain) to 3 (severe pain) for Pain score. Abbreviation: BoNT, Botulinum toxin; VAS, Visual Analogue Scale; NRS, Numeric rating scale; SPADI, Shoulder Pain and Disability Index; ROM, range of motion; SF-36, Short form-36; AE, Adverse event.

Share and Cite

MDPI and ACS Style

Hsu, P.-C.; Wu, W.-T.; Han, D.-S.; Chang, K.-V. Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials. Toxins 2020, 12, 251. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins12040251

AMA Style

Hsu P-C, Wu W-T, Han D-S, Chang K-V. Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials. Toxins. 2020; 12(4):251. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins12040251

Chicago/Turabian Style

Hsu, Po-Cheng, Wei-Ting Wu, Der-Sheng Han, and Ke-Vin Chang. 2020. "Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials" Toxins 12, no. 4: 251. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins12040251

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop